Compare Merck & Co., Inc. (MRK) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Xcel Energy Inc — how do they compare? Merck & Co., Inc. trades at $144.74 (market cap $351.28B), while Xcel Energy Inc trades at $73.3 (market cap $45.82B). The key difference: Merck & Co., Inc. is far larger — about 7.7× Xcel Energy Inc's market cap, and Xcel Energy Inc pays the higher dividend (3.23%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Xcel Energy Inc for 61 Days on average.
| MRK | XEL | |
|---|---|---|
Market Cap | $351.28B | $45.82B |
Volume | 7,969,665 | 6,910,516 |
Sector | Health | Utilities |
52-Week High | $156.43 | $83.91 |
52-Week Low | $82.49 | $69.39 |
Typical Hold Time | 98 Days | 61 Days |
Enterprise Value | $398.04B | $84.14B |
Dividend Yield | 2.39% | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Xcel Energy (XEL) trades at $72.42, down 0.43% with a bearish technical signal despite recent earnings beats. The stock shows solid fundamentals with $14.67B revenue, 15.28% net margin, and consistent cash flow growth. Analyst consensus is bullish with a $90.83 price target (62.96% buy rating), while institutional activity shows mixed positioning. Recent news highlights data center power demand growth and wildfire liability concerns.
XEL offers attractive utility exposure with 11% rate base growth potential and dividend stability, but faces regulatory and wildfire litigation risks. The current valuation at 20.1x P/E appears reasonable given earnings trajectory, though technical weakness near support at $71-72 requires monitoring for entry points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
